Farizky Humardani

Dr. Farizky Humardani


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Clinica Chimica Acta
Verified
Journal Article
Closed access
VBValentinus Besin
Valentinus Besin
TYTrilis Yulianti
Trilis Yulianti
PNPaulus Budiono Notopuro
Paulus Budiono Notopuro
Farizky HumardaniFarizky Humardani
Farizky Humardani

24 April 2025 in Chronic Diseases and Translational Medicine
Verified
Journal Article
Open access
VBValentinus Besin
Valentinus Besin
Farizky HumardaniFarizky Humardani
Farizky Humardani
FYFenny Lanawati Yudiarto
Fenny Lanawati Yudiarto
POPaulus Anam - Ong
Paulus Anam - Ong
SPSulistyo Emantoko Dwi Putra
Sulistyo Emantoko Dwi Putra
RNRatih Asmana Ningrum
Ratih Asmana Ningrum
Monoclonal antibodies (mAbs) have made significant progress in the treatment of Alzheimer's disease (AD). However, mAbs are associated with adverse effects, including Amyloid‐Related Imaging Abnormality (ARIA), which manifests as edema or effusion (ARIA‐E) and hemorrhage (ARIA‐H). The mechanisms behind these effects are not yet fully understood. Moreover, spontaneous ARIA has been insufficiently explored, and mAb therapies, particularly lecanemab, have mainly focused on patients with the APOE‐ε4 allele carrier. This review aims to address this gap by examining the mechanisms of spontaneous ARIA, ARIA induced by mAbs, and the influence of genetic variants on ARIA development. The autoantibody‐Aβ‐mediated immune response targets excessive Aβ deposits, increasing immune activity through microglial reactivity. The heightened immune response, driven by Aβ accumulation in blood vessels, promotes angiopathy and inflammation, potentially contributing to spontaneous ARIA. The APOE‐ε4 allele carrier is more strongly associated with ARIA‐E because it redistributes Aβ deposition from the brain to blood vessels, influencing microglial reactivity. The redistribution enhances vascular integrity and reduces the risk of ARIA‐H. However, it also increases the likelihood of ARIA‐E due to Aβ accumulation in the vasculature, triggering inflammation. In contrast, the development of ARIA‐H is linked to increased TREM2 expression and microglial reactivity, leading to impaired vascular integrity and disrupted matrix remodeling, which worsens the condition. Additionally, the adverse effects of mAbs may extend beyond the APOE‐ε4 allele, possibly impacting other genetic variants involved in microglial reactivity, Aβ redistribution, and vascular integrity.

13 March 2024 in Clinica Chimica Acta
Verified
Journal Article
Closed access
SPSulistyo Emantoko Dwi Putra
Sulistyo Emantoko Dwi Putra
Farizky HumardaniFarizky Humardani
Farizky Humardani
YAYulanda Antonius
Yulanda Antonius
JJJonathan Jonathan
Jonathan Jonathan
LMLisa Thalia Mulyanata
Lisa Thalia Mulyanata

18 December 2024 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ABAudrey Belinda
Audrey Belinda
Farizky HumardaniFarizky Humardani
Farizky Humardani
SPSulistyo Emantoko Dwi Putra
Sulistyo Emantoko Dwi Putra
BWBhanu Widyadhana
Bhanu Widyadhana

16 April 2024 in neurogenetics
Verified
Journal Article
Closed access
PDF file
VBValentinus Besin
Valentinus Besin
Farizky HumardaniFarizky Humardani
Farizky Humardani
TYTrilis Yulianti
Trilis Yulianti
SPSulistyo Emantoko Dwi Putra
Sulistyo Emantoko Dwi Putra
RTRina Triana
Rina Triana
MJMatthew Justyn
Matthew Justyn

Verified
Journal Article
Open access
PDF file
Fahrul NurkolisFahrul Nurkolis
Fahrul Nurkolis
Nurlinah AmaliaNurlinah Amalia
Nurlinah Amalia
Yosi Yohanes Putra TandiYosi Yohanes Putra Tandi
Yosi Yohanes Putra Tandi
Ariq Fadhil AthallahAriq Fadhil Athallah
Ariq Fadhil Athallah
Muhammad Reva AdityaMuhammad Reva Aditya
Muhammad Reva Aditya
RTRaymond R. Tjandrawinata
Raymond R. Tjandrawinata
The rs1801133 (C677T) polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene has been linked to type 2 diabetes (T2D) risk. This study aimed to assess the association between rs1801133 genotypes (CC, CT, TT) and T2D across multiethnic populations and to identify genotype- and region-specific risks. A global meta-epidemiological analysis was conducted using data from 19 studies comprising 6479 participants from Asia, Africa, Europe, and America. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by region were also performed. The results of the CC vs. CT dominant genetic model were OR 95% CI = 0.63 (0.46–0.87); p = 0.005; the CC vs. TT genetic recessive model yielded OR 95% CI = 0.59 (0.38–0.91); p = 0.02; and the CT vs. TT codominance genetic model yielded OR 95% CI = 0.95 (0.65–1.37); p = 0.78. Based on the subgroup analysis, the CC genotype is predominantly associated with an increased risk of T2D in both Africa and Europe. From this study, the CC genotype was proven to be highly contributory to T2D risk compared to the CT and TT genotypes. These findings highlight the need for ethnicity-informed genetic screening and targeted prevention strategies in global diabetes management.